CD8A and neoplasm: Furthermore, nimotuzumab activates adaptive immunity through tumor antigen- (TA-) specific CD8+ T cells and increases the expression of the human leukocyte antigen (HLA) class I-dependent antigen presentation molecule (known as signal 1) that allows induced T cells to recognize and kill EGFR+ tumor cells, reversing one EGFR-mediated mechanism of immune escape that can benefit tumors [10].